Advertisement

PARP Inhibition in Ovarian Cancer: State of the Science

      Polyadenosine 5’ diphosphosphoribose polymerase (PARP) inhibitors are a class of anti-cancer drugs designed to target tumors with deficits in homologous recombination. The best studied of these deficits are those associated with germline BRCA mutation (BRCAmut), but others have been recently identified as well. PARP inhibitors (PARPi) have distinct potential to change the paradigm of ovarian cancer treatment in comparison to other biologic agents for several reasons: ease of administration due to oral formulation, generally acceptable toxicity and tolerability, high frequency of deficits in homologous recombination in high grade serous ovarian cancer, and possible synergy with other targeted agents such as anti-angiogenic drugs [
      • Ledermann J.
      • Harter P.
      • Gourley C.
      • Friedlander M.
      • Vergote I.
      • Rustin G.
      • et al.
      Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • et al.
        Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
        N Engl J Med. 2012; 366: 1382-1392
        • Liu J.F.
        • Barry W.T.
        • Birrer M.
        • Lee J.M.
        • Buckanovich R.J.
        • Fleming G.F.
        • et al.
        Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
        Lancet Oncol. 2014; 15: 1207-1214
        • Oza A.
        • Cibula D.
        • Oaknin
        • Benzaquen A.
        • Poole C.
        • Mathijssen R.
        • et al.
        Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum sensitive recurrent serous ovarian cancer (PSR SOC): BRCA 1/2 mutation (BRCAm) and interim overall survival analyses.
        Eur J Cancer. 2013; 49
        • Kaufman B.
        • Shapira-Frommer R.
        • Schmutzler R.K.
        • Audeh M.W.
        • Friedlander M.
        • Balmana J.
        • et al.
        Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
        J Clin Oncol. 2014;
        • Audeh M.W.
        • Carmichael J.
        • Penson R.T.
        • Friedlander M.
        • Powell B.
        • Bell-McGuinn K.M.
        • et al.
        Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
        Lancet. 2010; 376: 245-251
        • Gelmon K.A.
        • Tischkowitz M.
        • Mackay H.
        • Swenerton K.
        • Robidoux A.
        • Tonkin K.
        • et al.
        Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
        Lancet Oncol. 2011; 12: 852-861
        • Kaye S.B.
        • Lubinski J.
        • Matulonis U.
        • Ang J.E.
        • Gourley C.
        • Karlan B.Y.
        • et al.
        Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
        J Clin Oncol. 2012; 30: 372-379
        • Coleman R.
        • Sill M.W.
        • Aghajanian C.
        • et al.
        A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation -- a Gynecologic Oncology Group study (abstract).
        Gynecol Oncol. 2014; 133
        • Matulonis U.A.
        • Berlin S.
        • Ivy P.
        • Tyburski K.
        • Krasner C.
        • Zarwan C.
        • et al.
        Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
        J Clin Oncol. 2009; 27: 5601-5606
        • Ledermann J.
        • Perren T.
        • Raja F.
        • et al.
        Randomized double blind phase III trial of cediranib (AZD 2171) in relapased platinum sensitive ovarian cancer: result of the ICON 6 trial.
        in: Presented at the 2013 Europeean Cancer Congress, Netherlands, Sept 13, 2013; abstract 10. 2013
        • Hegan D.C.
        • Lu Y.
        • Stachelek G.C.
        • Crosby M.E.
        • Bindra R.S.
        • Glazer P.M.
        Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
        Proc Natl Acad Sci U S A. 2010; 107: 2201-2206
        • Tentori L.
        • Lacal P.M.
        • Muzi A.
        • Dorio A.S.
        • Leonetti C.
        • Scarsella M.
        • et al.
        Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.
        Eur J Cancer. 2007; 43: 2124-2133
      1. (Available from:)
        • Oza A.
        • Cibula D.
        • Benzaquen A.
        • Poole C.
        • Mathijssen R.
        • Sonke G.
        Olaparib plus chemotherapy followed by maintenance monotherapy inpatients with platinum sensitive recurrent serous ovarian cancer (abstract).
        J Clin Oncol. 2012; 30
        • Lheureux S.
        • Ledermann J.
        • Kaye S.
        • Gourley C.
        • Friedlander M.
        • Bowtell D.
        • et al.
        J Clin Oncol. 2014; 32
        • Dougherty B.
        • Ledermann J.
        • Lai Z.
        • Robertson J.
        • Ho T.
        • Hodgson D.
        • et al.
        Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients with platinum-sensitive, relapsed serous ovarian cancer (abstract).
        J Clin Oncol. 2014; 32
        • Fenaux P.
        • Morel P.
        • Lai J.L.
        Cytogenetics of myelodysplastic syndromes.
        Semin Hematol. 1996; 33: 127-138
        • Liu J.F.
        • Konstantinopoulos P.A.
        • Matulonis U.A.
        PARP inhibitors in ovarian cancer: current status and future promise.
        Gynecol Oncol. 2014; 133: 362-369